Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions

Details

Ressource 1Download: Marzolini.pdf (154.28 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_70514994B951
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
UNIL/CHUV
Title
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions
Journal
Ann Intern Med
Author(s)
Marzolini C., Kuritzkes D. R., Marra F., Boyle A., Gibbons S., Flexner C., Pozniak A., Boffito M., Waters L., Burger D., Back D., Khoo S.
ISSN
1539-3704 (Electronic)
0003-4819 (Print)
ISSN-L
0003-4819
Publication state
Published
Issued date
05/2022
Peer-reviewed
Oui
Volume
175
Number
5
Pages
744-746
Language
english
Notes
Marzolini, Catia
Kuritzkes, Daniel R
Marra, Fiona
Boyle, Alison
Gibbons, Sara
Flexner, Charles
Pozniak, Anton
Boffito, Marta
Waters, Laura
Burger, David
Back, David
Khoo, Saye
eng
MR/V020498/1/MRC_/Medical Research Council/United Kingdom
MR/V028391/1/MRC_/Medical Research Council/United Kingdom
Editorial
Research Support, Non-U.S. Gov't
Ann Intern Med. 2022 May;175(5):744-746. doi: 10.7326/M22-0281. Epub 2022 Mar 1.
Abstract
Nirmatrelvir-ritonavir (NMV/r) is now being used to treat high-risk patients with mild to moderate COVID-19. This article provides advice to clinicians regarding recognition of medications likely to interact with NMV/r and suggests approaches to managing such drug-drug interactions. An algorithm is provided to assist in decision making.
Keywords
*covid-19, Drug Interactions, Humans, *Ritonavir/therapeutic use, SARS-CoV-2
URN
urn:nbn:ch:serval-BIB_70514994B9518
OAI-PMH
oai:serval.unil.ch:BIB_70514994B951
DOI
10.7326/M22-0281
Pubmed
35226530
Create date
25/08/2023 6:17
Last modification date
27/08/2023 7:12
Usage data